Lv41
700 积分 2023-06-30 加入
Discovery of Clinical Candidate GDC-8264, a Novel, Potent and Selective RIP1 Inhibitor for Amelioration of Tissue Damage and the Treatment of Inflammatory Diseases
5小时前
待确认
Discovery and Structure-Based Design of Macrocyclic Peptides Targeting STUB1
1个月前
已完结
Improved Solution-State Properties of Monoclonal Antibodies by Targeted Mutations
1个月前
已完结
Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer
1个月前
已完结
Optimization of therapeutic antibodies for reduced self-association and non-specific binding via interpretable machine learning
1个月前
已完结
Novel Macrocyclic NLRP3 Inhibitors
1个月前
已完结
Discovery of Pyridine-2-Carboxamides Derivatives as Potent and Selective HPK1 Inhibitors for the Treatment of Cancer
1个月前
已完结
Discovery of a Novel Macrocyclic Noncovalent CDK7 Inhibitor for Cancer Therapy
1个月前
已完结
Core Modifications of GSK3335103 toward Orally Bioavailable αvβ6 Inhibitors with Improved Synthetic Tractability
1个月前
已完结
Discovery of Novel Neo-Clerodane Derivatives as Potent Dual-Functional Antiosteoporosis Agents through Targeting Peroxisome Proliferator-Activated Receptor-γ
1个月前
已完结
皖公网安备34019202002308
